-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Corcept Therapeutics Inc quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2017 to Q1 2024.
- Corcept Therapeutics Inc Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was -$7.16M, a 6.48% decline year-over-year.
- Corcept Therapeutics Inc annual Deferred Income Tax Expense (Benefit) for 2023 was -$29.5M, a 13% increase from 2022.
- Corcept Therapeutics Inc annual Deferred Income Tax Expense (Benefit) for 2022 was -$33.9M, a 880% decline from 2021.
- Corcept Therapeutics Inc annual Deferred Income Tax Expense (Benefit) for 2021 was $4.35M, a 69.2% decline from 2020.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)